Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.

Schwartz S.

Curr Med Res Opin. 2008 Nov;24(11):3009-22. doi: 10.1185/03007990802390795 . Epub 2008 Oct 2. Review.

PMID:
18828960
2.

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

Pinelli NR, Cha R, Brown MB, Jaber LA.

Ann Pharmacother. 2008 Nov;42(11):1541-51. doi: 10.1345/aph.1L198. Epub 2008 Oct 28.

PMID:
18957626
3.

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.

Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M.

Diabetes Obes Metab. 2010 Dec;12(12):1058-65. doi: 10.1111/j.1463-1326.2010.01251.x.

PMID:
20977576
4.

Exenatide (Byetta) for type 2 diabetes.

[No authors listed]

Med Lett Drugs Ther. 2005 Jun 6;47(1210):45-6.

PMID:
15933616
5.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
6.

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.

Bi Y, Zhang B, Xu W, Yang H, Feng W, Li C, Tong G, Li M, Wang X, Shen S, Zhu B, Weng J, Zhu D.

Acta Diabetol. 2014 Oct;51(5):865-73. doi: 10.1007/s00592-014-0638-3. Epub 2014 Aug 14.

PMID:
25118999
8.

Exenatide may aggravate moderate diabetic renal impairment: a case report.

Johansen OE, Whitfield R.

Br J Clin Pharmacol. 2008 Oct;66(4):568-9. doi: 10.1111/j.1365-2125.2008.03221.x. Epub 2008 May 15. No abstract available.

9.

Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.

Wajcberg E, Tavaria A.

Expert Opin Pharmacother. 2009 Jan;10(1):135-42. doi: 10.1517/14656560802611832 . Review.

PMID:
19236187
10.

Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.

Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH.

Curr Med Res Opin. 2008 Sep;24(9):2437-47. doi: 10.1185/03007990802282398 . Epub 2008 Jul 24.

PMID:
18662495
11.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.

Iwamoto K, Nasu R, Yamamura A, Kothare PA, Mace K, Wolka AM, Linnebjerg H.

Endocr J. 2009;56(8):951-62. Epub 2009 Aug 25.

12.

Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus.

Papanas N, Katsiki N, Hatzitolios AI, Maltezos E.

Expert Opin Pharmacother. 2011 Jul;12(10):1457-61. doi: 10.1517/14656566.2011.568477.

PMID:
21651446
13.

[Exenatide convinces in a six-month study: HbA1c sunk significantly].

[No authors listed]

MMW Fortschr Med. 2009 May 7;151(19):51. German. No abstract available.

PMID:
19827448
14.

Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.

Perez A, Zhao Z, Jacks R, Spanheimer R.

Curr Med Res Opin. 2009 Dec;25(12):2915-23. doi: 10.1185/03007990903350011.

PMID:
19827910
15.

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD.

Diabetes Care. 2005 May;28(5):1083-91.

PMID:
15855571
16.

Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.

Murphy CE.

Ann Pharmacother. 2012 Jun;46(6):812-21. doi: 10.1345/aph.1Q722. Epub 2012 Jun 5. Review.

PMID:
22669803
17.

Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.

[No authors listed]

Prescrire Int. 2013 Jun;22(139):151. No abstract available.

PMID:
23885352
18.

Exenatide: new drug. Type 2 diabetes for some overweight patients.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):228-31.

PMID:
18087791
19.

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.

Diabetes Care. 2005 May;28(5):1092-100.

PMID:
15855572
20.

Exenatide for once-weekly administration.

[No authors listed]

Drug Ther Bull. 2012 Jul;50(7):78-80. doi: 10.1136/dtb.2012.06.0115.

PMID:
22789767

Supplemental Content

Support Center